Pharmacokinetic Models

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS
A SEMINAR ON by V. Sandeep Kumar M.Pharmacy, I Sem. Department of Pharmaceutics University College Of Pharmaceutical Sciences Kakatiya University Warangal.
Pharmacy 732 Winter Instructors William HaytonPharmaceutics James CoylePPAD Cari BrackettPPAD Kristin LugoPPAD Juhyun KimPharmaceutics.
Non compartmental analysis
Pharmacokinetics of Drug Absorption
Nonlinear pharmacokinetics
Two-compartment model
1 Intravenous Infusion Equations Some drugs are administered using a continuous intravenous infusion, and if the infusion is discontinued the serum concentration/time.
Determining Elimination Rate (K)
One-compartment open model: Intravenous bolus administration
Week 5- Pharmacokinetics of oral absorption
Pharmacokinetics Calculations
Week 3 - Biopharmaceutics and Pharmacokinetics
Index of Simulations 1-Compartment, IV bolus 1-Compartment, IV infusion: Steady- State1-Compartment, IV infusion: Steady- State 1-Compartment, IV infusion:
Practical Pharmacokinetics
Week 4 - Biopharmaceutics and Pharmacokinetics
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Toxicokinetic Calculations
Dosing Regimen Design Infusion regimen.
Gokaraju Rangaraju College of Pharmacy
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
INTRAVENOUS INFUSION.
VM 8314 Dr. Jeff Wilcke Pharmacokinetic Modeling (describing what happens)
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
Karunya Kandimalla, Ph.D. Assistant Professor, Pharmaceutics
Week 6- Bioavailability and Bioequivalence
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Nonlinear Pharmacokinetics
Pharmacokinetics Introduction
Multiple Dosing: Intermittent or multiple dose regimen
PHARMACOKINETIC MODELS
1-Compartment Oral Dosing 400 mg of moxifloxacin is administered orally to Mr BB, a 68 yr old male who weighs 75 kg. Blood samples were drawn following.
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Intravenous bolus administration: monitoring drug in urine
One Compartment Open Model IV bolus
The General Concepts of Pharmacokinetics and Pharmacodynamics
1 Single-dose kinetics Plasma [Drug] curve Upon administration [drug] plasma reaches a max Then begins to decline as the Drug is eliminated Cp max = max.
Noncompartmental Models. Introduction The noncompartmental approach for data analysis does not require any specific compartmental model for the system.
CHAPTER 7 ABSORPTION KINETICS.
Phoenix WinNonLin Assignment Due Today Access Phoenix remotely.
MS Phoenix WinNonLin Project
Nonlinear Pharmacokinetics
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Study Aids Anki Flash cards – Content that you need to know for the tests. MS Excel sheet with Calculations.
Multicompartment Models
ــــــــــــــ February 17 th, PHT - LECTURE Mathematical Fundamental in Pharmacokinetics Dr. Ahmed Alalaiwe.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Time Plasma Conc (hr) (mg/L) Below limit of detection 1 Compartment IV Analysis & Renal Elimination 500 mg of tobramycin.
Clearance: basic concept (in vitro) Update OCT 2010.
Objectives Compartment Modeling of Drugs Models describing drug concentration-time profiles Multi-compartment Models.
415 PHT Plasma Level – Time Curve
Pharmacokinetics 3rd Lecture
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Drug Response Relationships
Allie punke Pharmacokinetics tutoring Fall 2016
Physiology for Engineers
Allie punke Pharmacokinetics tutoring Fall 2016
Chapter 7 COMPARTMENT MODELS
Lecture-8 Biopharmaceutics
Allie punke Pharmacokinetics tutoring Fall 2016
CONCEPT OF PHARMACOKINETICS- ONE COMPARTMENT MODEL
PHARMACOKINETICS Allie punke
Applications of Pharmacokinetics
Quantitative Pharmacokinetics
PHARMACOKINETICS Allie punke
Therapeutic Drug Monitoring
Presentation transcript:

Pharmacokinetic Models One Compartment Model IV Bolus Absorption

One Compartment Model v Simplest compartmental model Body is assumed to behave as if it were a single, well stirred fluid. v CL I.V. Bolus Dose -dX/dt = CL•Cp -d(X/V)/dt = (CL/V)•Cp = -dCp/dt Cp = Cp,oe-(CL/V)t

Example: Dose = 300 mg, as iv bolus V = 35 L and CL = 2 L/h Cp,o = Dose/V = 300 mg ÷ 35 L = 8.57 mg/L

One Compartment Model Cp = Cp,oe-(CL/V)t log Cp = log Cp,o – (CL/V)t/2.3 Slope = -(CL/V)/2.3 -2.3Slope = CL/V = KE V = Dose ÷ Cp,o V = 300 mg ÷ 8.56 mg/L = 35 L CL = KEV

One Compartment Model -2.303 x Slope = KE Slope = (y2 – y1)/(x2 – x1) = (log Cp2 – log Cp1)/ ( t2 – t1) = log (Cp2/Cp1)/(t2 – t1) = log (7.65/1.10)/(2 – 36) = -0.0248 KE = (-2.303)(-0.0248) = 0.0571 h-1

One Compartment Model CL = KEV = (0.0571 h-1)(35 L) = 2 L/h Half Life: t1/2 = ln 2/KE = 0.693/0.0571 h-1 = 12 h t1/2 = 0.693 V/CL = 0.693•35L/2L h-1 = 12 h

One Compartment Model KEY CONCEPT! Half Life and KE depend on both CL and V; a change in either CL or V will cause a change in t1/2 and KE. KE t1/2 CL V

Area Under the Curve AUC = the area under the Cp,t profile, from time = 0 to time = , usually for a single dose. AUCt1-t2 = the area under the curve from time = t1 to time = t2.

Summary of Wednesday v I.V. Bolus Dose Cp = Cp,oe-(CL/V)t CL - 2.3 x Slope = CL/V = KE V = Dose ÷ Cp,o CL = KEV KE t1/2 CL V

Calculation of AUC Trapezoidal Method, R&T, p.469 2 3 2.4 1.8 Cp mg/L 1 2 4 8 Time [h] AUC = 1+2.5+5.4+8.4+6 = 23.3 mg•h/L

CL for individual pathways MB Murine CL = CLH + CLR + CLP CLH CLR DB Durine CLP Expired air

One Compartment Model A two-fold change in CL:

One Compartment Model A two-fold change in V:

One Compartment Model Absorption Input Drug enters body by a first-order, monoexponential process. ka dX/dt = kaXg - CL•Cp v CL

Absorption The slope of the log-linear phase reflects the smaller of ka and KE.

Absorption Shape parameters Cmax Tmax AUC t1/2 Use shape parameters to deduce changes in PK parameters: ka, CL, V, F

v CL ka Tmax At the peak Cp, dCp/dt = 0

v CL ka Cmax

AUC

ka ka  ___Cmax ___Tmax ___t1/2 ___AUC

CL CL  ___Cmax ___Tmax ___t1/2 ___AUC

F•Dose F•Dose  ___Cmax ___Tmax ___t1/2 ___AUC

V V  ___Cmax ___Tmax ___t1/2 ___AUC

Shape parameters as functions of PK parameters

Peak Shape Analysis

Peak Shape Analysis

PK Parameters from single-dose plasma concentration profile Uncertainty in ‘F’ is transmitted to CL. The ratio Dose/AUC gives the true value of CL only when F=1. If F1, then the calculation gives a CL value that is larger than the true value.

PK Parameters from single-dose plasma concentration profile -2.3 x slope = KE (usually)

Pharmacokinetic Models One Compartment Model Absorption Rate Bioavailability

Absorption Rate v XG = Dose•e-kat CL ka XG = Dose•e-kat How can the value of ka be determined from the Cp,t profile?

Determination of ka v XGI XB XE X = amount CL ka Determination of ka XGI XB XE X = amount XGI cannot be measured; ka must come from Cp,t profile

v CL ka Determination of ka 1. Computer fit of equation using software such as WinNonlin. 2. Graphical analysis; aka “method of residuals”, “feathering”, “peeling”

Method of Residuals When ka > 4KE, e-kat goes to 0 before e-KEt does. After e-kat goes to 0:

Method of Residuals Subtract the Cp,t profile from the line:

Method of Residuals What if KE > 4ka?

Bioavailability - F

Bioavailability - F When AUCstd is from an i.v. dose, Fstd = 1.00 and the “absolute bioavailability” of the test is determined. When AUCstd is somethingelse such as the innovator’s product or a solution, “relative bioavailability” is determined.